JPMorgan Chase & Co. Analysts Give BioNTech (NASDAQ:BNTX) a $183.00 Price Target

BioNTech (NASDAQ:BNTX – Get Rating) has been given a $183.00 price target by investment analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, Borsen Zeitung reports. JPMorgan Chase & Co.‘s price target indicates a potential upside of 21.85% from the stock’s current price.

Several other research analysts also recently commented on BNTX. Deutsche Bank Rese… set a $200.00 target price on BioNTech in a research note on Friday, April 1st. Zacks Investment Research downgraded BioNTech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 27th. TheStreet upgraded BioNTech from a “d+” rating to a “c-” rating in a research report on Wednesday, May 4th. UBS Group dropped their target price on BioNTech from $450.00 to $300.00 and set a “buy” rating for the company in a research report on Tuesday, April 5th. Finally, Morgan Stanley dropped their target price on BioNTech from $217.00 to $197.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 12th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $259.59.

Shares of BioNTech stock traded up $5.75 during trading hours on Tuesday, hitting $150.18. 30,695 shares of the company’s stock traded hands, compared to its average volume of 1,943,112. The company has a fifty day simple moving average of $157.49 and a 200-day simple moving average of $205.50. BioNTech has a 12-month low of $121.32 and a 12-month high of $464.00. The stock has a market capitalization of $37.07 billion, a price-to-earnings ratio of 3.25 and a beta of -0.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.33 and a quick ratio of 4.18.

BioNTech (NASDAQ:BNTX – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported $15.03 earnings per share for the quarter, topping the consensus estimate of $9.16 by $5.87. BioNTech had a return on equity of 142.70% and a net margin of 54.20%. The company had revenue of $6.37 billion during the quarter, compared to analyst estimates of $4.50 billion. During the same quarter last year, the firm posted $5.29 EPS. The firm’s revenue for the quarter was up 211.2% on a year-over-year basis. On average, analysts forecast that BioNTech will post 34.6 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of BNTX. PNC Financial Services Group Inc. increased its stake in shares of BioNTech by 226.0% during the third quarter. PNC Financial Services Group Inc. now owns 2,184 shares of the company’s stock valued at $596,000 after buying an additional 1,514 shares during the period. Truist Financial Corp boosted its position in shares of BioNTech by 45.9% during the third quarter. Truist Financial Corp now owns 3,327 shares of the company’s stock valued at $908,000 after purchasing an additional 1,047 shares in the last quarter. Mackenzie Financial Corp bought a new stake in shares of BioNTech during the third quarter valued at approximately $290,000. Picton Mahoney Asset Management bought a new stake in shares of BioNTech during the third quarter valued at approximately $164,000. Finally, Allianz Asset Management GmbH boosted its position in shares of BioNTech by 69.6% during the third quarter. Allianz Asset Management GmbH now owns 78,188 shares of the company’s stock valued at $21,344,000 after purchasing an additional 32,076 shares in the last quarter. 14.42% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile (Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Read More